Windlas Biotech uploads Q4FY26 conference call recording

0 min read Updated on 22 May 2026, 06:50 PM

Reviewed by

Anirudha BScanX News Team

AI Summary

Windlas Biotech Limited has uploaded the audio recording of its Q4FY26 conference call regarding audited financial results for the year ended March 31, 2026. The recording is accessible on the company website, with the transcript to be shared with exchanges and uploaded later.

*this image is generated using AI for illustrative purposes only.

Windlas Biotech Limited has announced that the audio recording of its recent Investors and Analyst conference call is now available. The discussion focused on the audited consolidated and standalone financial results for the quarter and financial year ended March 31, 2026.

The recording has been uploaded to the company's official website and can be accessed by stakeholders. This initiative follows the initial intimation regarding the conference call dated May 18, 2026.

Accessing the Recording

Stakeholders can listen to the proceedings via the specific link provided on the company's digital platforms. The management has confirmed that the transcript of the said call will be shared with the Stock Exchanges and subsequently uploaded on the website in due course.

Financial Context

The conference call provided a detailed review of the company's performance for the full fiscal year 2026 and the final quarter. The availability of the recording ensures that investors who missed the live session can still access the management's commentary and insights.

The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

What key revenue growth targets or guidance did Windlas Biotech's management outline for fiscal year 2027 during the conference call?

How might Windlas Biotech's FY2026 financial performance influence its contract development and manufacturing (CDMO) expansion strategy going forward?

Are there any upcoming product launches or therapeutic segment expansions that Windlas Biotech's management hinted at for the near term?

Read Next Article

Windlas Biotech FY26 Net Profit Rises 9% to Rs 66 Cr

1 min read Updated on 22 May 2026, 05:39 AM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

AI Summary

Windlas Biotech reported its highest ever revenue of Rs 904.09 crore for FY26, a 19% YoY increase, with a net profit of Rs 66.44 crore. The board recommended a dividend of Rs 6.30 per share and approved the buyback of 470,000 equity shares.

*this image is generated using AI for illustrative purposes only.

Windlas Biotech has announced its audited financial results for the quarter and financial year ended March 31, 2026. The company reported its highest ever revenue from operations at Rs 904.09 crore for FY26, a growth of 19% compared to Rs 759.88 crore in the previous year. Profit for the year stood at Rs 66.44 crore, registering a growth of 9% year-on-year from Rs 60.95 crore. The Board of Directors has recommended a dividend of Rs 6.30 per equity share of the face value of Rs 5 each, subject to shareholder approval.

For the quarter ended March 31, 2026, revenue from operations stood at Rs 238.50 crore, an increase of 18% from Rs 202.71 crore in the corresponding quarter of the previous year. Profit for the quarter was Rs 16.02 crore. Basic earnings per share (EPS) for FY26 rose to Rs 31.59 from Rs 29.03 in the previous year. The company reported a net liquidity position and remained net debt free.

Financial Performance

The company achieved its highest ever Adjusted EBITDA of Rs 121 crore in FY26, a 26% YoY growth, with a margin of 13.4%. Reported EBITDA for the year was Rs 105 crore. The Board meeting was held on May 21, 2026, to consider and approve the financial results.

Metric	FY26 (Rs. in crores)	FY25 (Rs. in crores)	Q4FY26 (Rs. in crores)	Q4FY25 (Rs. in crores)
Revenue from Operations	904.09	759.88	238.50	202.71
Adjusted EBITDA	121	97	33	26
Adjusted PAT	83	63	23	17
Reported PAT	66.44	60.95	16.02	16.29
Basic EPS (Rs.)	31.59	29.03	7.60	7.77

Operational Highlights

The Generic Formulations CDMO vertical recorded its highest ever revenue of Rs 664 crore in FY26, a 20% YoY growth, contributing 73% to the consolidated revenue. The Trade Generics & Institutional vertical reported revenue of Rs 195 crore, up 13% YoY. The Exports vertical grew by 40% to Rs 46 crore during the fiscal year.

During the year, the company completed a buyback of 470,000 fully paid-up equity shares at a price of Rs 1,000 per share, aggregating to Rs 47 crore.

With the Exports vertical growing 40% YoY to Rs 46 crore, which geographies or therapeutic segments is Windlas Biotech targeting to sustain and accelerate international expansion in FY27?

Given the gap between Adjusted PAT (Rs 83 crore) and Reported PAT (Rs 66.44 crore), what one-time charges or non-recurring items are likely to normalize in the coming fiscal year, and how might this impact future dividend payouts?

As the Generic Formulations CDMO vertical approaches Rs 700 crore in revenue, are there capacity expansion plans or new client acquisitions in the pipeline that could sustain the 20%+ growth trajectory?